Boston Scientific (BSX): financials, SEC filings and peers

Boston Scientific (BSX) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in Marlborough, Massachusetts.

It was founded in 1979 and joined the S&P 500 on February 24, 1995.

Its fiscal year ends in December, and its shares trade on the NYSE.

In its SEC filings it is classified as “Surgical & Medical Instruments & Apparatus”.

Boston Scientific at a glance

Revenue (12 months): $21.1B
Revenue growth: +8.9%
Operating margin: 18.7%
Net income (12 months): $3.5B
Free cash flow (12 months): $3.3B
Cash: $609M
Debt: $12.0B
Diluted EPS (12 months): $2.36

Twelve months to September 30, 2026, from the 10-Q filed November 2, 2026.

Latest twelve months

Over the twelve months to September 30, 2026, Boston Scientific reported revenue of $21.1 billion, up 8.9% from a year earlier.

Its operating margin was 18.7%: for every $100 of sales, about $19 was left as operating profit.

Net income was $3.5 billion (16.6% of revenue), 25.5% higher than a year earlier.

Operating cash flow was $4.2 billion and capital spending $903 million, leaving free cash flow of $3.3 billion (15.8% of revenue).

At the end of the period it held $609 million in cash and $12.0 billion in debt, a net debt position of $11.3 billion.

The diluted share count fell 2.9% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $9.9 billion in fiscal 2020 to $20.1 billion in fiscal 2025, about 15.2% a year.
Revenue has grown for 5 fiscal years in a row.
Operating margin widened from -0.8% to 18.0% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.
Boston Scientific reported a net loss in 1 of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$11.9B	$12.7B	$14.2B	$16.7B	$20.1B
Revenue growth	19.9%	6.7%	12.3%	17.6%	19.9%
Operating margin	10.1%	13.0%	16.5%	15.5%	18.0%
Net income	$1.0B	$698M	$1.6B	$1.8B	$2.9B
Free cash flow	$1.3B	$938M	$1.8B	$2.6B	$3.7B
Diluted EPS	$0.69	$0.45	$1.07	$1.25	$1.94

Fiscal years as reported in Boston Scientific’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

10-Q filed November 2, 2026 — quarterly report
8-K filed October 28, 2026 — Earnings results
8-K filed October 7, 2026 — Executive or director change; Other event
8-K filed September 23, 2026 — Executive or director change
8-K filed September 8, 2026
8-K filed August 26, 2026 — Other event
10-Q filed August 3, 2026 — quarterly report
8-K filed July 29, 2026 — Earnings results

All Boston Scientific filings on SEC EDGAR

Companies like Boston Scientific

Other S&P 500 companies in Health Care Equipment:

More from Health Care

All 60 Health Care companies →

Questions about Boston Scientific

Is Boston Scientific's revenue growing?

Yes. Revenue for the twelve months to September 30, 2026 was $21.1 billion, up 8.9% from a year earlier, according to its SEC filings.

Is Boston Scientific profitable?

Yes. It earned $3.5 billion in net income over the twelve months to September 30, 2026, a net margin of 16.6%.

Does Boston Scientific have more cash or more debt?

At September 30, 2026 it had $609 million in cash and $12.0 billion in debt, so more debt than cash.

When did Boston Scientific last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on November 2, 2026.

Which companies are similar to Boston Scientific?

In the S&P 500, Boston Scientific is grouped in Health Care Equipment within the Health Care sector. Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Dexcom (DXCM), Edwards Lifesciences (EW) are in the same group.

Understand the numbers

Source: Boston Scientific’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 10, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.